Chest
Volume 139, Issue 2, February 2011, Pages 237-238
Journal home page for Chest

Editorials
Could Vitamins Be Helpful to Patients With Sleep Apnea?

https://doi.org/10.1378/chest.10-2017Get rights and content

References (11)

There are more references available in the full text version of this article.

Cited by (14)

  • Circulating biomarkers to identify cardiometabolic complications in patients with Obstructive Sleep Apnea: A systematic review

    2019, Sleep Medicine Reviews
    Citation Excerpt :

    However, prospective studies are required to determine if other markers are associated with risk of accelerated renal dysfunction. An ideal prognostic OSA biomarker should be disease-specific, treatment-sensitive, exist in a causal pathway, and predict improvements in outcome [47]. Previous reviews focused on identifying unique OSA signatures that highlighted inflammatory, metabolic, and oxidative stress molecules as potential markers [11], however prognostic biomarkers haven't been systematically explored [13,48].

  • Biomarkers associated with obstructive sleep apnea: A scoping review

    2015, Sleep Medicine Reviews
    Citation Excerpt :

    During the search for this elusive screening tool, special interest has centered around potential OSA biomarkers. The ideal biomarker should be highly sensitive and specific for OSA, should be dose-responsive and correlate to severity of disease, and should be involved in an important causal pathway, so that changes in the biomarker levels reliably predict improvements in the outcome [13]. Several different OSA biomarkers have been proposed over the last 14 y. However, to the best of our knowledge, no scoping review has been conducted thus far to critically examine what we currently know on the potential viability and use of biomarkers in OSA diagnosis and management.

  • Overview of proteomics studies in obstructive sleep apnea

    2015, Sleep Medicine
    Citation Excerpt :

    Shih and Malhotra identified properties of an ideal biomarker for OSA, which should be highly sensitive, specific, dose-responsive, and correlate with the severity of the disease. The biomarker or set of biomarkers should serve as a measure of adequacy of therapy and be involved in the causal pathway, therefore being useful for predicting outcome [63,64]. The pioneering work of Shah et al. (2006) on serum proteome profiling in pediatric OSA patients is in concordance with criteria for an ideal OSA biomarker [52].

  • Biomarkers associated with obstructive sleep apnea and morbidities: A scoping review

    2015, Sleep Medicine
    Citation Excerpt :

    The discovery of an ideal biomarker for OSA-associated morbidity has the potential to provide information related to prognosis and response to treatment [5]. Ideal biomarkers should be highly sensitive and specific for OSA-induced end-organ dysfunction should be involved in an important causal pathway, so that changes in the biomarker levels in the context of OSA treatment reliably predict improvements in the specific end-organ outcome [23]. Several different morbidity biomarkers have been proposed for OSA over the last 12 years.

  • Proceedings from the 2011 American association of oral and maxillofacial surgeons research summit

    2012, Journal of Oral and Maxillofacial Surgery
    Citation Excerpt :

    Recent studies have focused on the development of potential biomarkers for OSA. The ideal biomarker would have 1 of the following characteristics: 1) high sensitivity and specificity for detecting disease; 2) a dose-response correlation with the severity of disease; 3) an ability to detect a response to treatment and to allow the measurement of treatment efficacy; and 4) involvement in a known causal pathway that, when changed, provides a reliable surrogate outcome measurement.46 Currently, no ideal biomarker exists.

View all citing articles on Scopus

Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Malhotra has received consulting and/or research income from Philips, Sepracor, Pfizer, Merck, Apnex, Itamar, Cephalon, Sleep Group Solutions, Sleep Health Centers, Medtronic, and Ethicon. Dr Shih has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

© 2011 American College of Chest Physicians Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).

View full text